CASE COMMENTS: UNILATERAL PRACTICES - EXCLUSIONARY ABUSE – PHARMACEUTICAL INDUSTRY

Exclusionary abuse : The Paris Court of Appeals dismisses a claim of a pharmaceutical laboratory against a French Competition Authority’s decision imposing a sanction for an exclusionary abuse against a generic manufacturer (Sanofi)

*This article is an automatic translation of the original article, provided here for your convenience. Read the original article. The Paris Court of Appeals confirms the decision handed down by the French Competition Authority in the case of the disparagement practices implemented by Sanofi against generic drugs competing with its originator product, Plavix, whose active ingredient is clopidogrel, used in the prevention of cardiovascular accidents linked to arterial wall lesions (atherothrombosis). The patents protecting Plavix expired in July 2008. However, Sanofi still enjoys additional protection related to the type of salt used (clopidogrel hydrogen sulfate) and another related to the treatment of acute coronary syndrome in combination with aspirin. Faced with the arrival of

Access to this article is restricted to subscribers

Already Subscribed? Sign-in

Access to this article is restricted to subscribers.

Read one article for free

Sign-up to read this article for free and discover our services.

 

PDF Version

Author

  • Côte d’Azur University, GREDEG (Nice)

Quotation

Frédéric Marty, Exclusionary abuse : The Paris Court of Appeals dismisses a claim of a pharmaceutical laboratory against a French Competition Authority’s decision imposing a sanction for an exclusionary abuse against a generic manufacturer (Sanofi), 18 December 2014, Concurrences N° 1-2015, Art. N° 71087, p. 102

Visites 210

All reviews